Table 2.

Comparisons between patients with and without sarcopenia

Sarcopenic (n = 14; 25.5%)Nonsarcopenic (n = 41; 74.5%)P
Toxicity
Present7 (50.0%)8 (20%)0.03
Absent7 (50.0%)33 (80%)
ECOG performance status*
No performance impairment (scores 0-1)9 (64%)25 (65%)1.00
Performance impairment (scores 2-3)5 (36%)14 (35%)
Estrogen receptor status
Positive8 (57%)31 (76%)0.31
Negative6 (43%)10 (24%)
HER-2 status
Positive3 (21%)15 (37%)0.35
Negative11 (79%)26 (63%)
Characteristics mean (SD)
Age56.6 (11.4)54.1 (10.1)0.43
Weight (kg)65.6 (11.4)71.4 (16.7)0.23
Height (m)1.6 (0.1)1.6 (0.1)0.11
BMI (kg/m2)24.6 (4.0)27.8 (5.7)0.06
BSA (m2)1.7 (0.2)1.8 (0.2)0.42
Albumin†39.8 (4.9)39.1 (4.5)0.60
Lumbar skeletal muscle index (cm2/m2)35.0 (3.3)47.4 (5.0)<0.0001
Whole body lean mass (kg)34.0 (3.3)42.5 (5.0)<0.0001
Mg capecitabine/kg LBM104.2 (16.1)86.9 (13.7)<0.0001
Toxicity prevalence‡
Hand-foot syndrome3 (21%)4 (8%)0.35
Diarrhea4 (29%)1 (2.4)0.01
Stomatitis5 (36%)2 (4.9%)0.008
Nausea3 (21%)3 (7%)0.17
Vomit1 (7%)1 (2.4)0.45
Neutropenia1 (7.1%)00.25

  • ↵* ECOG performance status score missing for one patient (n = 54).

  • ↵† Albumin status missing for 2 patients (n = 53).

  • ↵‡ Grade 2 or higher toxicity (associated with dose delays or reductions).